Search clinical trials for: Indacaterol xinafoate 400 μg

Total 175 results

Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Rennes University Hospital

Completed

Fludrocortisone in Healthy Volunteers (AFLUCO4) (AFLUCO4)

Healthy Volunteers

France
Alebund Pty Ltd

Completed

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

Healthy Subjects

Australia
Novartis

Completed

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Spain, Belgium, Italy, Canada, Denmark, United States
AstraZeneca

Completed

Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Type 2 Diabetes

Japan
Novartis Pharmaceuticals

Completed

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Spain, United States, Belgium
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis

Completed

12-week Efficacy of Indacaterol

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Judit Pich Martínez

Completed

A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

HIV-infection

Spain
Novartis Pharmaceuticals

Completed

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

Mild Asthma

Germany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Alebund Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

Healthy Subjects
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg

Healthy

United States
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment

Psoriasis Vulgaris

Taiwan
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Spain, Canada, Slovakia, India, Netherlands, Czech Republic, Hungary
AstraZeneca

Completed

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo (LAC-MD-27)

Chronic Obstructive Pulmonary Disease

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Pharmacokinetic

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
AstraZeneca

Completed

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Healthy Volunteers

China
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
Novartis Pharmaceuticals

Completed

Cardiac Safety of Indacaterol

Chronic Obstructive Pulmonary Disease | Healthy Volunteers

United States
Baylor College of Medicine
George Washington University; Children's National Research Institute

Completed

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Hookworm Infection | Hookworm Disease

United States
Trinomab Biotech Co., Ltd.
TIGERMED AUSTRALIA PTY LIMITED

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults

Healthy Adult Subjects

Australia
Organon and Co

Terminated

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)

Contraception
AstraZeneca

Completed

Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease (COPD)

Belgium, Germany
Tris Pharma, Inc.
Forest Laboratories

Completed

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Prolonged QTc Interval | Pharmacokinetic

United States
AstraZeneca

Completed

Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate (ALIGHT-COPD)

Chronic Obstructive Pulmonary Disease

Romania, Czech Republic
Ardea Biosciences, Inc.

Completed

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

Healthy

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

Korea, Republic of
Debiopharm International SA

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

Healthy Volunteers

United Kingdom
Assiut University

Completed

Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section

Pruritus
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands

3

Subscribe